Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03820414 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

A Phase 1 study of Herpes Zoster and Varicella Zoster, sponsored by Curevo.

Completed
Registry status
Phase 1
Development phase
90
Enrollment target
1
Study location

NCT03820414: Completed Phase 1 study of Herpes Zoster and Varicella Zoster, sponsored by Curevo.

NCT03820414 is a Phase 1 study of Herpes Zoster and Varicella Zoster that has completed, run by Curevo. The registered enrollment target is 90 participants, below the 2,168-participant average among 16 other Herpes Zoster trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03820414, a Phase 1 study of Herpes Zoster and Varicella Zoster, has completed, sponsored by Curevo.

COMPLETED
Registry status
Phase 1
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.

Conditions Studied

Herpes Zoster Varicella Zoster

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL CRV 101

Study Locations (1)

Missouri

  • The Center for Pharmaceutical Research - Kansas City

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2019-01-03
Est. Completion 2020-04-30
Phase Phase 1
Curevo

2 total trials

What the finished NCT03820414 record still lists

NCT03820414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 2,168-participant average among 16 other Herpes Zoster trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03820414 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT03820414 about?

NCT03820414 is a clinical study titled "Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects". The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.

What is the current status of trial NCT03820414?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2019-01-03. Estimated completion is 2020-04-30.

What conditions does trial NCT03820414 study?

This clinical trial studies the following conditions: Herpes Zoster, Varicella Zoster.

What interventions are being tested in trial NCT03820414?

The interventions under investigation include: Placebo (BIOLOGICAL), CRV 101 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03820414?

This trial is sponsored by Curevo, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03820414 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Zoster

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03820414's enrollment target sits among peer trials

90 16th of 16 higher than 1 of 16 other Herpes Zoster trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03820414, the US trial registry maintained by the National Library of Medicine. NCT03820414 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.